Literature DB >> 2113784

A clinician's guide to cost-effectiveness analysis.

A S Detsky1, I G Naglie.   

Abstract

Cost-effectiveness analysis can be used to help set priorities for funding health care programs. For each intervention, the costs and clinical outcomes associated with that strategy must be compared with an alternate strategy for treating the same patients. If an intervention results in improved outcomes but also costs more, the incremental cost per incremental unit of clinical outcome should be calculated. The incremental cost-effectiveness ratios for various programs can be ranked to set funding priorities. By using this list, the person responsible for allocating resources can maximize the net health benefit for a target population derived from a fixed budget. Clinicians may not share this objective because, individually, they are appropriately concerned solely with the effectiveness of a specific intervention for their patients and are not concerned with the benefit derived from spending those resources on other patients in the target population. In addition, allocation may be driven by distributional and political objectives. Nevertheless, cost-effectiveness analysis demonstrates the consequences of allocation decisions. Because clinicians should participate in policy making, they must understand d the role of this technique in setting funding priorities.

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Year:  1990        PMID: 2113784     DOI: 10.7326/0003-4819-113-2-147

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  97 in total

1.  Costs in Perspective: Understanding Cost-Effectiveness Analysis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 2.  Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging.

Authors:  D J Seidenwurm; C H McDonnell; N Raghavan; J Breslau
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

3.  Cost-effective management of common bile duct stones: a decision analysis of the use of endoscopic retrograde cholangiopancreatography (ERCP), intraoperative cholangiography, and laparoscopic bile duct exploration.

Authors:  D R Urbach; Y S Khajanchee; B A Jobe; B A Standage; P D Hansen; L L Swanstrom
Journal:  Surg Endosc       Date:  2001-01       Impact factor: 4.584

4.  Decision trees and fuzzy logic: a comparison of models for the selection of measles vaccination strategies in Brazil.

Authors:  L Ohno-Machado; R Lacson; E Massad
Journal:  Proc AMIA Symp       Date:  2000

Review 5.  Understanding cost effectiveness: a detailed review.

Authors:  A F Smith; G C Brown
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

6.  Economic analysis of randomized, controlled trials.

Authors:  G H Lyman
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 7.  Prevention of type 2 diabetes: the strategic approach for implementation.

Authors:  P E H Schwarz; A L Albright
Journal:  Horm Metab Res       Date:  2011-12-07       Impact factor: 2.936

8.  Evidence to support development of pharmacy services: how much or how little do we need?

Authors:  Scot H Simpson
Journal:  Can J Hosp Pharm       Date:  2010-03

9.  Novel monoclonal antiendotoxin antibody therapy: efficacy at any price?

Authors:  W K Fant
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

10.  Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.

Authors:  José-Luis Fernandez; Stuart Montgomery; Clément Francois
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.